FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera
Results showed that following 7.5 years of treatment with ropeginterferon alfa-2b-njft, 61% of patients achieved a complete hematological response, which was defined as hematocrit less than 45% without phlebotomy for at least 2 months since last phlebotomy, platelet counts of 400 x 109/L or less, leukocytes
Results showed that following 7.5 years of treatment with ropeginterferon alfa-2b-njft, 61% of patients achieved a complete hematological response, which was defined as hematocrit less than 45% without phlebotomy for at least 2 months since last phlebotomy, platelet counts of 400 x 109/L or less, leukocytes